All systems go as US UDI deadline looms: FDA fine-tunes provisions
This article was originally published in Clinica
Executive Summary
Jay Crowley , senior advisor to the US FDA on patient safety, explains how the agency is faring with its mandate to introduce a unique device identification system in the country. Neena Brizmohun, of Clinica’s sister publication Scrip Regulatory Affairs, reports
You may also be interested in...
New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Merck Sharp & Dohme's Ebola vaccine, Ervebo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The Stakes Are High So Get It Right
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. Consultant Kate Dion highlights to In Vivo helpful tips for companies facing this daunting situation.
Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: